Sunho Biologics (02898) Releases February 2026 Monthly Return

Bulletin Express

03/02

Sunho Biologics, Inc. (02898) submitted its Monthly Return for Equity Issuer for the period ended 28 February 2026 on 02 March 2026. According to the announcement, the company’s total authorized share capital remains at 200.00 million ordinary shares, each with a par value of USD 0.0005, amounting to USD 100,000. The number of issued shares remains unchanged at 156.67 million, with no treasury shares reported.

The public float requirement for its listed ordinary shares is confirmed at 25%, and no changes in share options, warrants, or convertible securities were noted for the reporting period. The document was submitted by Chairman and Executive Director Zhang Feng.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1198797795"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1198797795\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1198797795?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-02 17:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1198797795","market":"hk","top_or_hot":-1,"title":"Sunho Biologics (02898) Releases February 2026 Monthly Return","media":"Bulletin Express","content":"<p>Sunho Biologics, Inc. (02898) submitted its Monthly Return for Equity Issuer for the period ended 28 February 2026 on 02 March 2026. According to the announcement, the company’s total authorized share capital remains at 200.00 million ordinary shares, each with a par value of USD 0.0005, amounting to USD 100,000. The number of issued shares remains unchanged at 156.67 million, with no treasury shares reported.</p>\n<p>The public float requirement for its listed ordinary shares is confirmed at 25%, and no changes in share options, warrants, or convertible securities were noted for the reporting period. The document was submitted by Chairman and Executive Director Zhang Feng.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sunho Biologics (02898) Releases February 2026 Monthly Return</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSunho Biologics (02898) Releases February 2026 Monthly Return\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-03-02 17:26</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Sunho Biologics, Inc. (02898) submitted its Monthly Return for Equity Issuer for the period ended 28 February 2026 on 02 March 2026. According to the announcement, the company’s total authorized share capital remains at 200.00 million ordinary shares, each with a par value of USD 0.0005, amounting to USD 100,000. The number of issued shares remains unchanged at 156.67 million, with no treasury shares reported.</p>\n<p>The public float requirement for its listed ordinary shares is confirmed at 25%, and no changes in share options, warrants, or convertible securities were noted for the reporting period. The document was submitted by Chairman and Executive Director Zhang Feng.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02898","symbol_name":"盛禾生物-B","start_time":0,"source_url":"","article_id":"1198797795","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1198797795","pubTimestamp":1772443614,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Sunho Biologics, Inc. (02898) submitted its Monthly Return for Equity Issuer for the period ended 28 February 2026 on 02 March 2026. According to the announcement, the company’s total authorized...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02898":"盛禾生物-B"},"translate_title":"顺和生物(02898)发布2026年2月月报表","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02898":1},"content_text":"Sunho Biologics, Inc. (02898) submitted its Monthly Return for Equity Issuer for the period ended 28 February 2026 on 02 March 2026. According to the announcement, the company’s total authorized share capital remains at 200.00 million ordinary shares, each with a par value of USD 0.0005, amounting to USD 100,000. The number of issued shares remains unchanged at 156.67 million, with no treasury shares reported.\nThe public float requirement for its listed ordinary shares is confirmed at 25%, and no changes in share options, warrants, or convertible securities were noted for the reporting period. The document was submitted by Chairman and Executive Director Zhang Feng.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}